Hologic Signs Definitive Agreement to Acquire Reveal Genomics

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Consumer

Women

Genetics

Biotechnology

Reveal Genomics

More Like This

The company appoints Ana Vivancos, Ph.D., as Director of NGS and Genomic Technologies; Joel Parker, Ph.D., as Chief Scientific Officer; and Aleix Prat, M.D., Ph.D., as Chairman of the Board of Directors.

REVEAL GENOMICS Aligns Founder Leadership With Priorities to Support Long-term Growth, Scientific Excellence, and Global Partnerships

Groundbreaking Study Confirms Clinical Decision Impact of HER2DX® Genomic Assay in Early-Stage HER2-Positive Breast Cancer

SABCS 2025: REVEAL GENOMICS Presents Major Advance in Predicting Brain Metastasis in HER2+ Breast Cancer

HER2DX studies presented at ASCO.

ASCO 2025: REVEAL GENOMICS Unveils New HER2DX Data From 800+ Patients

REVEAL GENOMICS and Ona Therapeutics Join Forces to Advance Next-generation Cancer Treatment

REVEAL GENOMICS® HER2DX® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast Cancer

Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company

Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer